89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company's common stock to four new employees (the "Inducement Grants") on November 25, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年11月29日，美国加州旧金山（全球新闻专线）- 89bio公司（以下简称"公司"或"89bio"）（纳斯达克股票代码：ETNB）是一家临床阶段生物制药公司，专注于开发和商业化治疗肝脏和心脏代谢疾病的创新疗法。今日，公司董事会薪酬委员会批准了向四名新员工发放非合格股票期权，购买公司普通股总数为49,800股（以下简称"诱因授予"），日期为2024年11月25日（以下简称"授予日期"）。诱因授予根据公司的2023年诱因计划（以下简称"计划"）授予。根据纳斯达克上市规则5635(c)(4)，诱因授予是为了吸引这些个人按照规定的日期与89bio公司签订雇佣协议而授予的。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
诱因授予的行权价格等于89bio公司在授予日期的收盘价。诱因授予将在四年内解锁，员工入职一周年之日解锁25%的股份，其后剩余股份将分为12个等额季度解锁，取决于员工在适用解锁日期时继续受雇于89bio。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit or follow the company on LinkedIn.
关于89bio 89bio是一家专注于为患有肝脏和代谢性疾病的患者开发最佳疗法的临床阶段生物制药公司。该公司致力于通过临床发展其领先候选药物pegozafermin，用于治疗代谢性功能障碍相关脂肪肝（MASH）和严重高三酰甘油血症（SHTG）。Pegozafermin是一种经过特殊设计的、潜在的最佳成长因子21类似物（FGF21类似物），通过糖基PEG化技术优化生物活性，并具有延长半衰期的特点。公司总部位于旧金山。欲了解更多信息，请访问www.89bio.com或关注该公司的
89bio是一家专注于开发肝脏和心脏代谢疾病患者的最佳疗法的临床阶段生物制药公司，这些患者缺乏最佳的治疗选择。该公司正在进行其主力候选药peg卡费明治疗代谢功能紊乱相关性脂肪肝（MASH）和严重高三酰甘油血症（SHTG）的3期研究。Pegozafermin是一种经过特殊设计的、具有独特的糖基PEG化技术的可能是最佳的成纤维细胞生长因子21（FGF21）类似物，通过延长半衰期来优化生物活性。该公司总部设在旧金山。欲了解更多信息，请访问或关注该公司的LinkedIn。
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投资者联系人：
Annie Chang
89bio公司
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒体联系：
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
